中美癌痛诊疗指南药学对比解读

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (561 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Drug therapy is the most important and commonly used method for the treatment of cancer pain. Regular and effective drug therapy can relieve 80%-90% of the pain symptoms of cancer patients. For a long time, the Clinical Practice Guidelines for Adult Cancer Pain issued by the National comprehensive cancer network (NCCN) of the United States in January every year has been one of the important references for doctors around the world in the diagnosis and treatment of cancer pain. The former National Health and Family Planning Commission of China issued two versions of the Standards for the Diagnosis and Treatment of Cancer Pain in 2011 and 2018 respectively. The guidelines of the two countries are different in the suggestions of the aspects of pain assessment, pain grade, dose titration, maintenance medication, dose conversion, opioids reduction and the prevention and treatment of opioid adverse reactions. In this paper, from the perspective of clinical pharmacists, the classification and comparative interpretation of the diagnosis and treatment of cancer pain in China and the United States are carried out, hoping to provide pharmaceutical suggestions for clinicians in the diagnosis and treatment of cancer pain.

Key words： Cancer pain Guidelines Pharmacy Interpretation Comparison

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Hui1 RAO Yuefeng2

Cite this article:

LI Hui1 RAO Yuefeng2. Comparative analysis of Chinese and American guidelines for the diagnosis and treatment of cancer pain[J]. 中国医药导报, 2021, 18(9): 4-7.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I9/4

[1] Liu WC，Zheng ZX，Tan KH，et al. Multidimensional Treatment of Cancer Pain [J]. Curr Oncol Rep，2017，19（2）：10-11.
[2] 梁继珍，易基群.广州市基层医院癌痛规范化治疗现状及障碍因素分析[J].临床肿瘤学杂志，2016，21（1）：66-70.
[3] 金建波，李菁，金孙洁，等.基层医院癌痛麻醉药品使用及其认知度的调查分析[J].现代诊断与治疗，2016，27（8）：1412-1414.
[4] 中华人民共和国卫生健康委员会.癌症疼痛诊疗规范（2018年版）[J].临床肿瘤学杂志，2018，23（10）：937-944.
[5] Benson AB，Venook AP，Al-Hawary MM，et al. Small Bowel Adenocarcinoma，Version 1.2020，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2019，17（9）：1109-1133.
[6] Swarm RA，Paice JA，Anghelescu DL，et al. Adult Cancer Pain，Version 3.2019，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2019，17（8）：977-1007.
[7] Im EO，Liu Y，Kim YH，et al. Asian American cancer patients’pain experience [J]. Cancer Nurs，2008，31（3）：17-23.
[8] 胡夕春，王杰军，常建华，等.癌症疼痛诊疗上海专家共识（2017年版）[J].中国癌症杂志，2017，27（4）：312-320.
[9] 李小梅，董艳娟，李慧莉，等.阿片耐受与慢性癌痛的阿片类药物治疗[J].中国疼痛医学杂志，2012，18（9）：561-565.
[10] Ratka A. The role of a pharmacist in ambulatory cancer pain management [J]. Curr Pain Headache Rep，2002，6（3）：191-196.
[11] Neufeld NJ，Elnahal SM，Alvarez RH. Cancer pain：a review of epidemiology，clinical quality and value impact [J]. Future Oncol，2017，13（9）：833-841.
[12] Fallon M，Hanks G，Chemy N. Principles of control of cancer pain [J]. BMJ，2006，332（7548）：1022-1024.
[13] Wu XH，Cui F，Zhang C，et al. Low-dose dexmedetomidine improves sleep quality pattern in elderly patients after noncardiac surgery in the intensive care unit：a pilot randomized controlled trial [J]. Anet Anesthesia Network，2017，21（5）：979-991.
[14] 王昆，金毅.难治性癌痛专家共识（2017年版）[J].中国肿瘤临床，2017，44（16）：787-793.
[15] 饶媚，林文宏，赖剑锋.创建癌痛规范化治疗示范病房对麻醉药品处方行为的影响[J].临床合理用药杂志，2019， 12（28）：106-107.
[16] Fallon M，Giusti R，Aielli F，et al. Management of cancer pain in adult patients：ESMO Clinical Practice Guidelines [J]. Ann Oncol，2018，29（S4）：149-174.
[17] Mercadante S，Marchetti P，Cuomo A，et al. Breakthrough pain and its treatment：critical review and recommendations of IOPS（Italian Oncologic Pain Survey）expert group [J]. Supportive Care in Cancer，2016，24（2）：961-968.
[18] Esparza-Mi?觡ana JM. Diagnosis and treatment of breakthrough pain [J].Med Clin：Barc，2018，150（3）：114-118.
[19] 郝伟，赵敏.未雨绸缪：美国阿片类药物危机给我国带来的启示[J].中华精神科杂志，2018，51（5）：287-292.
[20] 安徽省肿瘤质量控制中心癌痛专家组.安徽省癌症疼痛诊疗专家共识（2019年版）[J].安徽医药，2020，24（5）：1041-1047.
[21] 支梦佳，魏兴梅，高翔，等.我国阿片类镇痛药物临床使用现状分析[J].药物流行病学杂志，2018，27（6）：400-405.
[22] 罗盛.美国NCCN成人癌痛指南解读[J].中国处方药，2014，12（1）：4-6.
[23] Chen C，Tang S，Chen C. Meta-analysis of cultural difference in western and Asian patients [J]. Palliat Med，2011， 26（3）：206-211.
[24] 北京市疼痛治疗质量控制和改进中心癌痛专家组.北京市癌症疼痛管理规范（2017年版）[J].中国疼痛医学杂志，2017，23（12）：881-889.
[25] Bennett MI，Eisenberg E，Ahmedzai SH，et al. Standards for the management of cancer-related pain across Europe-A position paper from the EFIC Task Force on Cancer Pain [J]. Eur J Pain，2018，23（4）：660-668.
[26] Wickham RJ. Cancer Pain Management：Opioid Analgesics，Part 2 [J]. J Adv Pract Oncol，2017，8（6）：588-607.